Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.

What symbol and exchange does Evommune shares trade?

Evommune trades on the NYSE stock market under the symbol EVMN.

What is Evommune stock price doing today?

As of November 13, 2026, EVMN stock price declined to $7.63 with 718,127 million shares trading.

What is Evommune's Beta?

EVMN has a beta of 0.64, meaning it tends to be less sensitive to market movements. EVMN has a correlation of 0.00 to the broad based SPY ETF.

How much is Evommune worth?

EVMN has a market cap of $276.91 million. This is considered a Small Cap stock.

How much money does Evommune make?

Last quarter Evommune reported $0 in Revenue and -$.85 earnings per share. This fell short of revenue expectation by $-600,000 and missed earnings estimates by -$.02.

What are the top ETFs holding Evommune?

The top ETF exchange traded funds that EVMN belongs to (by Net Assets): VTI, IWM, VXF, FESM, IWO.

Is Evommune (EVMN) a good investment?

EVMN has underperformed the market in the last year with a return of -58.1%, while the SPY ETF gained +13.4%. In the last 3 month period, EVMN fell short of the market, returning -45.8%, while SPY returned -2.8%. However, in the most recent 2 weeks EVMN has outperformed the stock market by returning +13.4%, while SPY returned -0.2%.

What are the support and resistance levels for Evommune (EVMN)?

EVMN support price is $7.43 and resistance is $8.61 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EVMN shares will trade within this expected range on the day.